Bayer: results for prostate cancer treatment

(CercleFinance.com) - Results from the pivotal phase III ARANOTE trial evaluating darolutamide combined with androgen deprivation therapy (ADT) showed a statistically significant increase in radiological progression-free survival (rPFS) compared with placebo combined with ADT in patients with hormone-sensitive metastatic prostate cancer.


Darolutamide combined with ADT now shows positive data both with and without placebo.

The safety analysis reconfirms darolutamide's tolerability profile as observed in the ARAMIS and ARASENS trials.

' With the positive results of the ARANOTE study, which add to the data from the ARASENS study, darolutamide has now demonstrated solid efficacy and safety, with or without chemotherapy, in the treatment of metastatic cervical cancer. If regulatory approval is granted, physicians will have greater flexibility to tailor treatment to individual patient needs," said Fred Saad, Professor and Chairman of the Department of Surgery and Director of the Department of Genitourinary Oncology at the Université de Montréal, and principal investigator of the ARANOTE study.

Copyright (c) 2024 CercleFinance.com. All rights reserved.